WOMEN'S MULTIZONAL EVALUATION OF ANOGENITAL NEOPLASIA: WOMEN STUDY
Research type
Research Study
Full title
WOMEN'S MULTIZONAL EVALUATION OF ANOGENITAL NEOPLASIA: WOMEN STUDY
IRAS ID
229262
Contact name
Andreia Albuquerque
Contact email
Sponsor organisation
HOMERTON UNIVERSITY HOSPITAL NHS TRUST
Duration of Study in the UK
0 years, 11 months, 30 days
Research summary
Homerton Anal Neoplasia Service (HANS) is a reference UK Center for screening, diagnosing and treatment of anal intraepithelial neoplasia (precancerous lesions of anal cancer). This study is a retrospective analysis of the data from HANS from 2012 to March 2017 to identify and include all women who attended during this period. Our aim is to evaluate the prevalence, risk factors and treatment outcome of anogenital multizonal neoplasia in a cohort of high-risk women who attended this Service. Multizonal Anogenital Neoplasia is defined as the presence of high-grade lesions (precancerous lesions) or cancer concurrently in two or more of the following sites or zones: Perianal, Anal canal, Vulva, Vagina or Cervix. Previous studies on this topic have only included a small number of cases and information regarding multizonal anogenital neoplasia in is lacking. HANS is a specialist centre that deals with both genital and anal neoplasia concurrently providing access to a large information of high risk women. Multizonal assessment might be essential to diagnose occult areas of high-grade disease or carcinoma in high risk women. A better understanding of this high-risk population is needed, especially adopted for the population that is going to be screened and towards improving patient care.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
17/LO/1159
Date of REC Opinion
25 Jul 2017
REC opinion
Favourable Opinion